""upside vs downside"" — Epstein Files Search

Search Entities About Settings

/to search

Dataset

Sort

Status

DOJ Status

Date Range

–

Page Count

–

18 results for “"upside vs downside"”

Keyboard Shortcuts

/

Focus search

Esc

Blur input

O

Open PDF

←→

Paginate

EFTA00702577Set 9

2016-07-282p1,007w

along with the conversion ratio sliding scale, can result in an attractively skewed upside vs downside profile. AGN - BAML reaffirming BUY on US1listed AGN after FTC approval of generics sale

https://www.justice.gov/epstein/files/DataSet%209/EFTA00702577.pdf

EFTA02454699Set 11

2016-08-1518p3,484w

along with the conversion ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02454699.pdf

EFTA01785499Set 10

2016-08-1519p3,544w

along with the conversion ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01785499.pdf

EFTA02454261Set 11

2016-08-1517p3,300w

along with the conversion ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02454261.pdf

EFTA01157277Set 9

rate products, based on Atronis proprietary research of the inherent asymmetry in upside vs. downside USURPS...7% volatility driven by the seniority of these instruments in the sovereign capital structure

https://www.justice.gov/epstein/files/DataSet%209/EFTA01157277.pdf

EFTA00505976Set 9

rate products, based on Atronis proprietary research of the inherent asymmetry in upside vs. downside USURPS...7% volatility driven by the seniority of these instruments in the sovereign capital structure

https://www.justice.gov/epstein/files/DataSet%209/EFTA00505976.pdf

EFTA02454560Set 11

2016-08-1517p3,377w

with the conversion ratio sliding scale, can result in an att=actively skewed upside vs downside profile for holding the mandatory conve=t vs the common stock. Allergan, Teva

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02454560.pdf

EFTA00821594Set 9

2016-08-088p2,362w

along with the conversion ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergen, Teva and Frontier

https://www.justice.gov/epstein/files/DataSet%209/EFTA00821594.pdf

EFTA01783152Set 10

2016-08-0812p2,582w

along with the conversion ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01783152.pdf

EFTA01737698Set 10

2016-08-0914p2,836w

along with the conversion ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01737698.pdf

EFTA01783231Set 10

2016-08-0813p2,785w

along with the conversion ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01783231.pdf

EFTA00822153Set 9

2016-08-044p1,564w

along with the conversion ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergen, Teva and Frontier

https://www.justice.gov/epstein/files/DataSet%209/EFTA00822153.pdf

EFTA00821586Set 9

2016-08-086p2,186w

along with the conversion ratio sliding scale, can result In an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. EFTA00821588 Allergan, Teva

https://www.justice.gov/epstein/files/DataSet%209/EFTA00821586.pdf

EFTA02454071Set 11

2016-08-0812p2,677w

with the conversion ratio sliding scale, can result in an att=actively skewed upside vs downside profile for holding the mandatory conve=t vs the common stock. Allergan, Teva

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02454071.pdf

EFTA02455318Set 11

2016-08-0915p2,997w

with the conversion ratio sliding scale, can result in an att=actively skewed upside vs downside profile for holding the mandatory conve=t vs the common stock. Allergan, Teva

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02455318.pdf

EFTA01784854Set 10

2016-07-091p176w

much risk to have go . she is careless abou= what things she says . upside vs downside.=C240 not there. =please note The information contained in this communication is =onfidential

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01784854.pdf

EFTA00824186Set 9

2016-07-091p126w

much risk to have go . she is careless about what things she says . upside vs downside. not there. please note The information contained in this communication is confidential

https://www.justice.gov/epstein/files/DataSet%209/EFTA00824186.pdf

EFTA00692051Set 9

2016-07-091p174w

much risk to have go . she is careless about what things she says upside vs downside. not there. please note The information contained in this communication is confidential

https://www.justice.gov/epstein/files/DataSet%209/EFTA00692051.pdf

Results by Dataset18 total

Set 9

8

Set 10

5

Set 11

5

Corpus: 1990-03-17 – 2025-12-01

July 2016

Mo

Tu

We

Th

Fr

Sa

Su

None

Light

Medium

Heavy